Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices to protect customer data.

NBCC: The company has successfully sold 446 residential units at Aspire Silicon City in Noida through an e-auction, generating Rs 1,468 crore in sales. Additionally, it will receive a marketing fee of ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...

Microsoft Corp. today announced the launch of Microsoft Discovery, a new enterprise-grade artificial intelligence platform ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

23andMe was founded 19 years ago to provide saliva-based genetic testing of health and ancestry to consumers, going public in ...

The clinical trial for the potential vaccine, VLA15, began in August 2022. Stage 3 trials got underway in late 2023, ...

Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.